Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 12 years of age or older~* acne vulgaris with facial involvement~* A score of 3 (Moderate) or 4 (Severe) on the Investigator's Global Assessment Scale (inflammatory)~* 25 to 75 inflammatory lesions (papules and pustules) on the face (including the nose)~Exclusion Criteria:~* More than two acne nodules/cysts on the face~* Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne, etc.), or severe acne requiring systemic retinoid treatment~* Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea~* Beard or facial hair which might interfere with study assessments~* planning excessive exposure to sun or ultraviolet light during the study (i.e. natural or artificial sunlight, including tanning booths and sun lamp)~* Use of oral contraceptives solely for control of acne~* Liver function test alanine transaminase (ALT) and/or aspartate transaminase (AST) 2.5 times above upper limit of normal~* Renal function test serum creatinine at 150 umol/L (17 mg/L) or higher~* Presence of oral or genital candidiasis or history of multiple episodes of oral or genital candidiasis~* Females who intend to conceive a child within 5 months following Baseline visit~* Males who intend to conceive a child with partner during the study period~* Requiring concomitant use of methoxyflurane

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD2475/101 40 mg (Type: EXPERIMENTAL): Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
- Doxycycline 100 mg (Type: ACTIVE_COMPARATOR): Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).